People vaccinated three times or immunised after an earlier COVID-19 infection have comparable neutralising antibody response to those with a breakthrough infection, according to a study.
A breakthrough infection is a case of illness in which a fully vaccinated individual becomes infected.
The study, published in the journal Cell, looked at the strength, durability and breadth of neutralising antibody response generated by breakthrough infections in individuals vaccinated against SARS-CoV2.
The researchers at the University of Washington in the US noted that the Delta and Omicron coronavirus variants have enhanced transmissibility and immune evasion compared to the original virus.
These characteristics, and the waning of immunity from vaccines, have led to breakthrough infections in vaccinated individuals, they said.
The study found that the degree of antibody response depended on whether a person has had one, two, three, or four exposures to the spike protein through infection, vaccination, or a mixture of the two.
The spike protein is used by the SARS-C0V-2 virus to enter and infect cells.
The researchers checked antibody response in a group of individuals who had been vaccinated after having COVID-19.
They also analysed the antibodies in people who were previously vaccinated and experienced a breakthrough infection, those who were vaccinated only, and individuals who were boosted.
The team found that people who had received three-vaccine doses, those vaccinated after recovering from COVID-19, and those with a breakthrough infection had almost comparable neutralising antibody responses, in terms of magnitude and breadth.
Their blood serum binding and antibody neutralising responses to the spike protein in the coronavirus variants were much more potent and lasting than those generated by people who had received only two doses of vaccine.
This observation suggested that the increased number of exposures to SARS-CoV-2 antigens, either through infection and vaccination or triple vaccination, enhanced the quality of antibody responses, the researchers said.
They also investigated neutralisation of the divergent Omicron SARS-CoV-2 variant of concern that is driving the current wave of infections globally.
Their findings showed that boosted individuals had neutralising antibodies at similar levels to subjects vaccinated twice against the original ancestral strain.
This suggests a large amount of immune evasion, but that vaccine boosters can help close the neutralising antibody gap caused by Omicron, the researchers added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)